Xcellerated T cells (Cyclacel Pharmaceuticals)

N/A

Report date: 2022/11/25 17:01:46

Base Information

Drug NameXcellerated T cells (Cyclacel Pharmaceuticals)

Drug Alias NameXcyteDynabeadsActivated T cells

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionImmunostimulantsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCyclacel Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute Xcyte Therapies Inc

Active IndicationsN/A

Inactive IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin +[4]

Other Information

ATC CodeN/A